REGULATORY

Japan OKs Zetia Generic, Possibly AG, towards December Listing; No Entry for Lyrica This Time

August 16, 2019
The Ministry of Health, Labor and Welfare (MHLW) on August 15 gave the thumbs-up to a slew of generic drugs ahead of the next generic reimbursement listing in December, including what might be an authorized generic (AG) version of MSD/Bayer’s…

To read the full story

Related Article

REGULATORY

By Shinya Sato

Japan’s push to expand biosimilar use is running into a troubling supply problem. All seven ingredients that made their biosimilar…

By Kohei Hori

A Japanese health ministry proposal to impose steeper price cuts on certain medicines deemed to carry poor cost-effectiveness profiles cleared…

By Hayate Horiguchi

A Japanese drug pricing panel on November 11 discussed ways to respond to the US most-favored-nation (MFN) policy, with healthcare…

By Hayate Horiguchi

Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…

By Shunsuke Tani

Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…

Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…

Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…

The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…

Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…

Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…